Clarithromycin
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Clarithromycin: From Bacterial Infections to Hyperamylasemia
One-Sentence Summary
Clarithromycin is a macrolide antibiotic widely used for respiratory tract infections, skin and soft tissue infections, and Mycobacterium avium complex (MAC) disease, as well as Helicobacter pylori eradication regimens. The TxGNN model predicts a potential association with Hyperamylasemia, with 0 clinical trials and 1 case report currently available — suggesting the connection is mechanistically indirect rather than a direct therapeutic application.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (macrolide antibiotic; no Saudi Arabia authorizations on record) |
| Predicted New Indication | Hyperamylasemia |
| TxGNN Prediction Score | 99.35% |
| Evidence Level | L4 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is a cornerstone agent in treating Mycobacterium avium complex (MAC) and Mycobacterium abscessus pulmonary infections, and also exerts immunomodulatory effects by downregulating pro-inflammatory cytokines (IL-6, IL-8, TNF-α).
The predicted link to hyperamylasemia is indirect and secondary, not a direct therapeutic effect on serum amylase. TxGNN most likely constructed this connection through a knowledge graph path: clarithromycin → treats MAC/M. abscessus infection → mycobacterial infection can trigger infectious pancreatitis → pancreatitis elevates serum amylase (hyperamylasemia). A secondary pathway also exists: clarithromycin itself has been reported in very rare cases to cause drug-induced pancreatitis, which would also produce hyperamylasemia.
The sole supporting publication (PMID 15228140) describes a case of M. abscessus pulmonary infection complicated by primary macroamylasemia — illustrating co-occurrence of mycobacterial disease and elevated amylase, not a clarithromycin treatment effect directed at amylase levels. Hyperamylasemia is a laboratory finding rather than a primary disease target, and no evidence supports clarithromycin as a treatment for hyperamylasemia independent of its antimicrobial indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15228140 | 2004 | Case Report | Nihon Kokyuki Gakkai zasshi (Japanese Respiratory Society) | M. abscessus pulmonary infection in a 76-year-old man complicated with primary macroamylasemia; illustrates co-occurrence of mycobacterial infection and elevated amylase — not a direct clarithromycin treatment effect on amylase levels |
Saudi Arabia Market Information
Clarithromycin is not currently marketed in Saudi Arabia. No SFDA product authorizations were found in the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted link between clarithromycin and hyperamylasemia is mechanistically indirect (MAC infection → secondary pancreatitis → elevated amylase) and supported only by a single 2004 case report describing co-occurrence rather than therapeutic benefit. Hyperamylasemia is a laboratory marker, not an actionable treatment target in its own right, making this a low-priority repurposing candidate.
To proceed, the following is needed:
- Clarify the clinical question: if the goal is to treat hyperamylasemia caused by MAC/M. abscessus infection, clarithromycin's role as the primary antimicrobial is already well-established and no new repurposing study is required; if the goal is to treat hyperamylasemia of other etiologies, a mechanistic rationale must first be established
- Mechanism of action data (MOA) from DrugBank to complete mechanistic gap analysis (DG002)
- Saudi Arabia package insert and SFDA label data for safety screening (DG001)
- If this indication is to be pursued further, a systematic literature review covering macrolide effects on pancreatic amylase secretion is needed as a prerequisite to any research protocol design
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.